𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevalence of the rhesus-negative phenotype in caucasian patients with small-cell lung cancer (SCLC)

✍ Scribed by T. Cerny; M. F. Fey; R. Oppliger; M. Castiglione; B. Nachbur; M. Gertsch; A. Gasser; R. A. Joss; N. Thatcher; M. Lind; A. von Rohr; U. E. Nydegger

Publisher
John Wiley and Sons
Year
1992
Tongue
French
Weight
380 KB
Volume
52
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

We report that the Rhesus (Rh)-negative phenotype is more prevalent in patients with small-cell lung cancer (SCLC) than in the normal Caucasian population (SCLC: 25% Rh-negative vs. 15% expected, p < 0.000 I). This finding has been validated for a Central and a Northern European population (Switzerland and UK). In contrast, the Rh-negative phenotype is no more frequent in non-small-cell lung cancer patients or in heavy smokers with coronary heart disease than in the general population. There was a normal distribution of the ABO blood group phenotype in all patients studied. Whilst the significance of this observation is unclear, we hypothesize that a genetic predisposition to the development of SCLC may be linked to a hitherto unidentified gene on chromosome I p near the Rh locus. Our observation may perhaps allow further progress to be made in understanding genetic mechanisms of SCLC carcinogenesis.

πŸ“œ SIMILAR VOLUMES

Detection of the neural cell adhesion mo
Detection of the neural cell adhesion molecule (NCAM) in serum of patients with small-cell lung cancer (SCLC) with β€œlimited” or β€œextensive” disease, and bone-marrow infiltration
✍ J. A. Ledermann; F. Pasini; Y. Olabiran; G. Pelosi πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 French βš– 416 KB

The neural cell adhesion molecule (NCAM) is a tumourrelated antigen found on the surface of small-cell lung cancer (SCLC). NCAM exists in several molecular forms, including a soluble isoform. We have measured serum levels of NCAM using an enzyme immunoassay with 2 anltibodies, NCC-LU-246 and NCC-LU-

The results of treatment in 100 patients
The results of treatment in 100 patients with limited-stage small cell lung cancer
✍ Xuyi Liu; Xiaokui Li; Yubin Pang; Qingqi Li; Xueyi Wang; Wenjong Shen πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 472 KB πŸ‘ 2 views

## Background: In an attempt to improve treatment results of small cell lung cancer (sclc), combined induction chemotherapy and thoracic and prophylactic brain radiation therapy were administered. ## Method: From december 1980 to december 1987, 112 patients with limited-stage sclc were treated wi

Use of the immunotoxin N901-blocked rici
Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer
✍ Carol Epstein; Tom Lynch; Jeremy Shefner; Patrick Wen; Deirdre Maxted; Virginia πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 French βš– 365 KB

In patients with small-cell lung cancer (SCLC), relapse with resistant disease often causes deatlh. N90 I -blocked ricin (N90 I -bR), a murine monoclonal antibody (MAb)-blocked rich immunotoxin, is a potential therapeutic: for SCLC. N90 I -bR targets CD56, present on SCLC and cells of neuro-ectoderm

The effects of cyclosporine on the pharm
The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
✍ Daniel A. Rushing; Susan R. Raber; Keith A. Rodvold; Stephen C. Piscitelli; Gary πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 723 KB

Background. The authors compared the pharmacokinetics of doxorubicin when administered with and without concomitant high dose cyclosporine for multidrug resistant (MDR) tumor modulation in small cell lung cancer. Methods. Eight patients with small cell lung cancer served as their own controls and w